At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field’s approach to the cancer. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss Revolution’s daraxonrasib, other readouts to watch for in pancreatic cancer and what else is on BioCentury’s radar at this year’s American Society of Clinical Oncology meeting. BioCentury’s a...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from BioCentury This Week
Ep. 369 - ASCO advances, China innovation & U.S. science under threat
Ep. 367 - FDA, obesity targets and the rise of DACs
Ep. 366 - Europe's need for speed: Bio€quity takeaways
Ep. 365 - Thin ice for Makary, redosing AAVs
Get summaries like this every morning.
Free AI-powered recaps of BioCentury This Week and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.